ADORA2A and breast neoplasm: As a matter of fact, recent study repoted that pharmacological and genetic targeting of A2AR substantially enhanced the clinical efficacy of CAR-T-cell therapy by promoting their activation, effector cytokine production and antitumor activity in breast tumor-bearing mice (68).